Receptos Begins Enrollment Of Phase 3 Trial Of RPC1063 In Relapsing Multiple Sclerosis

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO, Jan. 6, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. announced today that the Company has enrolled the first patients in the Phase 3 portion of RADIANCE, its Phase 2/3 study of RPC1063 in relapsing multiple sclerosis (RMS). The announcement follows the review of interim analysis of the Phase 2 portion of the study which was announced in December 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news